Nyxoah (NYXH) Net Income towards Common Stockholders (2021 - 2026)
Nyxoah's (NYXH) quarterly Net Income towards Common Stockholders came in at $19.0 million in Q1 2026, down 19.19% year-on-year from $23.5 million in Q1 2025, and down 99.93% quarter-over-quarter from $27.4 billion in Q4 2025.
Nyxoah (NYXH) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Nyxoah's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $19.0 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 19.19% year-over-year to $19.0 million in Q1 2026; TTM through Mar 2026 was $27.4 billion, a 249.9% increase from a year earlier, with the FY2025 full-year figure at -$104.9 million, down 65.66% from the prior year.
- Net Income towards Common Stockholders slipped to $19.0 million in Q1 2026 per NYXH's latest filing, from $27.4 billion in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $27.4 billion in Q4 2025 and bottomed at -$18.3 billion in Q4 2024.
- The 5-year median for Net Income towards Common Stockholders is $12.9 million (2024), against an average of -$196.5 million.
- Across the five-year window, Net Income towards Common Stockholders surged 167934.78% in 2023 and plunged 245.57% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$13.6 billion in 2022, then climbed by 13.68% to -$11.7 billion in 2023, then slumped by 56.36% to -$18.3 billion in 2024, then surged by 249.36% to $27.4 billion in 2025, then tumbled by 99.93% to $19.0 million in 2026.
- Per Business Quant, the three latest NYXH Net Income towards Common Stockholders figures stand at $19.0 million (Q1 2026), $27.4 billion (Q4 2025), and -$27.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.32 Bn | 121.10 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 44.69 Bn | 43.88 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Alcon | 32.80 Bn | 31.14 Bn | 1.53 Bn | 22.13 Bn |
| 4 | Medline | 32.72 Bn | 30.49 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 29.54 Bn | 27.88 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.56 Bn | 23.13 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 14.00 Bn | 13.44 Bn | 1.10 Bn | 13.00 Mn |
| 8 | Cooper Companies | 13.75 Bn | 13.61 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Align Technology | 12.03 Bn | 10.97 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Nyxoah | 53.92 Mn | 100.91 Mn | 4.26 Mn | 19.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.03 Mn |
| Dec 31, 2025 | 27.37 Bn |
| Sep 30, 2025 | -27.60 Mn |
| Jun 30, 2025 | 23.06 Mn |
| Mar 31, 2025 | 23.55 Mn |
| Dec 31, 2024 | -18.33 Bn |
| Sep 30, 2024 | 18.96 Mn |
| Jun 30, 2024 | 14.22 Mn |
| Mar 31, 2024 | 12.93 Mn |
| Dec 31, 2023 | -11.72 Bn |
| Sep 30, 2023 | 8.30 Mn |
| Jun 30, 2023 | 13.99 Mn |
| Mar 31, 2023 | 12.81 Bn |
| Dec 31, 2022 | -13.58 Bn |
| Sep 30, 2022 | -6.29 Mn |
| Jun 30, 2022 | 5.34 Mn |
| Mar 31, 2022 | -7.64 Mn |
| Dec 31, 2021 | -7.24 Bn |
| Sep 30, 2021 | 10.40 Mn |
| Jun 30, 2021 | 8.36 Mn |